Deals

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps
HKG: 2607SHA: 601607

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607; SHA: 601607) announced that it has renewed its Sales and Distribution Agreement with Shanghai Fudan‑Zhangjiang Bio‑Pharmaceutical Co., Ltd. (HKG: 1349). Under the agreement,…

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AstraZenecaAZ

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Bio-Thera SolutionsBiosimilars

Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution

AIC&Y Pharmaceutical

C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV

Cell-therapyuBriGene Biosciences

uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors

Show More